Found 185 clinical trials
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.
We are currently recruiting participants for a clinical research study to evaluate the efficacy of an investigational medication in adults with Diabetic Kidney Disease.
- 12 views
- 14 Jan, 2021
- 1 location
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted
- 2 views
- 05 Dec, 2020
- 67 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Neurology
-
Currently Recruiting
Activity Study of Bevacizumab With Temozolomide Irinotecan for Neuroblastoma in Children
questions: does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used
- 57 views
- 30 Mar, 2020
- 10 locations
-
Phase 4 trial
-
Accepting pediatric ages
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
effect on vascular endothelial growth factor and CD 133.
- 0 views
- 01 Mar, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti
- 5 views
- 08 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2VEGFR-2, Induces Transporter Pgp function in vitro. This study in patients with advanced cancer
- 0 views
- 29 Mar, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Pediatrics/Neonatology
-
Currently Recruiting
Study of Apatinib as an Inhibitor of Tumor Angiogenesis
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the
- 0 views
- 07 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2VEGFRFGFRfibroblast growth factor receptor
- 0 views
- 13 Apr, 2020
- 6 locations
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more
- 0 views
- 08 Jul, 2019
- 1 location
-
Phase 2 trial
-
Accepting pediatric ages
-
An interventional trial
-
For all genders
-
Currently Recruiting
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP
- 4 views
- 07 Nov, 2020
- 1 location